

Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/DAEDE20136C3EN.html>

Date: October 2022

Pages: 286

Price: US\$ 2,500.00 (Single User License)

ID: DAEDE20136C3EN

Abstracts

Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Drugs In Development, 2022, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 18, 14, 2, 83, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Diabetic Retinopathy - Overview
- Diabetic Retinopathy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Diabetic Retinopathy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Diabetic Retinopathy - Companies Involved in Therapeutics Development
- Diabetic Retinopathy - Drug Profiles
- A-717 - Drug Profile
- Product Description
- Mechanism Of Action
- A-91 - Drug Profile
- Product Description
- Mechanism Of Action
- afibercept - Drug Profile
- Product Description
- Mechanism Of Action
- afibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- afibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- afibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- AIC-104 - Drug Profile
- Product Description
- Mechanism Of Action

AMD/DR - Drug Profile
Product Description
Mechanism Of Action
AMTX-100 - Drug Profile
Product Description
Mechanism Of Action
APTA-1004 - Drug Profile
Product Description
Mechanism Of Action
APX-3330 - Drug Profile
Product Description
Mechanism Of Action
AR-13503 SR - Drug Profile
Product Description
Mechanism Of Action
ARVN-006 - Drug Profile
Product Description
Mechanism Of Action
AST-202 - Drug Profile
Product Description
Mechanism Of Action
AT-003 - Drug Profile
Product Description
Mechanism Of Action
AVD-302 - Drug Profile
Product Description
Mechanism Of Action
AVMX-116 - Drug Profile
Product Description
Mechanism Of Action
axitinib SR - Drug Profile
Product Description
Mechanism Of Action
BAT-5906 - Drug Profile
Product Description
Mechanism Of Action
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action

BI-764524 - Drug Profile

Product Description

Mechanism Of Action

BI-765128 - Drug Profile

Product Description

Mechanism Of Action

Bi-specific Monoclonal Antibodies for Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

Biologic for Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

Biologics to Antagonize Semaphorin 3A for Diabetic Retinopathy and Retinopathy -
Drug Profile

Product Description

Mechanism Of Action

Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile

Product Description

Mechanism Of Action

BNC-1601 - Drug Profile

Product Description

Mechanism Of Action

BNN-27 - Drug Profile

Product Description

Mechanism Of Action

bosentan - Drug Profile

Product Description

Mechanism Of Action

brolocizumab - Drug Profile

Product Description

Mechanism Of Action

BT-2 - Drug Profile

Product Description

Mechanism Of Action

CCT-101 - Drug Profile

Product Description

Mechanism Of Action

CD-52 - Drug Profile

Product Description

Mechanism Of Action
Cell Therapy For Diabetic Retinopathy - Drug Profile
Product Description
Mechanism Of Action
cibinetide - Drug Profile
Product Description
Mechanism Of Action
CLT-020 - Drug Profile
Product Description
Mechanism Of Action
CRB-217 - Drug Profile
Product Description
Mechanism Of Action
deulinoleate ethyl - Drug Profile
Product Description
Mechanism Of Action
Diabetic Retinopathy - Drug Profile
Product Description
Mechanism Of Action
Drug for Diabetic Retinopathy and Retinopathy of Prematurity - Drug Profile
Product Description
Mechanism Of Action
EB-102 - Drug Profile
Product Description
Mechanism Of Action
EB-105 - Drug Profile
Product Description
Mechanism Of Action
EG-401 - Drug Profile
Product Description
Mechanism Of Action
EG-Mirotin - Drug Profile
Product Description
Mechanism Of Action
ELB-00824 - Drug Profile
Product Description
Mechanism Of Action
emixustat hydrochloride - Drug Profile
Product Description

Mechanism Of Action

ENN-0403 - Drug Profile

Product Description

Mechanism Of Action

ENN-106 - Drug Profile

Product Description

Mechanism Of Action

faricimab - Drug Profile

Product Description

Mechanism Of Action

FB-216A12 - Drug Profile

Product Description

Mechanism Of Action

fenofibrate - Drug Profile

Product Description

Mechanism Of Action

finerenone - Drug Profile

Product Description

Mechanism Of Action

FNP-120 - Drug Profile

Product Description

Mechanism Of Action

FP-008 - Drug Profile

Product Description

Mechanism Of Action

Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Diabetes Induced Eye Complications - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Diabetic Retinopathy, Neurodegenerative Diseases and Wet Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

GLY-230 - Drug Profile

Product Description

Mechanism Of Action

GYT-088 - Drug Profile

Product Description

Mechanism Of Action

HL-190 - Drug Profile

Product Description

Mechanism Of Action

HP-TAT - Drug Profile

Product Description

Mechanism Of Action

IM-201 - Drug Profile

Product Description

Mechanism Of Action

imatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

IVMED-60 - Drug Profile

Product Description

Mechanism Of Action

JP-153 - Drug Profile

Product Description

Mechanism Of Action

KIO-101 - Drug Profile

Product Description

Mechanism Of Action

KNP-301 - Drug Profile

Product Description

Mechanism Of Action

KSI-501 - Drug Profile

Product Description

Mechanism Of Action

KTH-223 - Drug Profile

Product Description

Mechanism Of Action

LKA-651 - Drug Profile

Product Description

Mechanism Of Action

MDH-001 - Drug Profile

Product Description

Mechanism Of Action

MDH-101 - Drug Profile

Product Description

Mechanism Of Action

metformin - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies for Age Related Macular Degeneration and Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies for Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies to Inhibit SCG3 for Oncology, Ophthalmology and Diabetic Complications - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody for Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Agonize Frizzled receptor 4 and LRP5 for Diabetic Retinopathy and Retinopathy of Prematurity - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

MR-MC-01 - Drug Profile

Product Description

Mechanism Of Action

MS-553 - Drug Profile

Product Description

Mechanism Of Action

NAV-2729 - Drug Profile

Product Description

Mechanism Of Action

NB-2222 - Drug Profile
Product Description
Mechanism Of Action
New Chemical Entities - Drug Profile
Product Description
Mechanism Of Action
NG-004 - Drug Profile
Product Description
Mechanism Of Action
NM-108 - Drug Profile
Product Description
Mechanism Of Action
NN-2101 - Drug Profile
Product Description
Mechanism Of Action
NS-001 - Drug Profile
Product Description
Mechanism Of Action
NTX-101 - Drug Profile
Product Description
Mechanism Of Action
OCU-200 - Drug Profile
Product Description
Mechanism Of Action
OCX-063 - Drug Profile
Product Description
Mechanism Of Action
OPL-0401 - Drug Profile
Product Description
Mechanism Of Action
OTT-166 - Drug Profile
Product Description
Mechanism Of Action
P-016 - Drug Profile
Product Description
Mechanism Of Action
Peptagon - Drug Profile
Product Description
Mechanism Of Action

PF-07 - Drug Profile

Product Description

Mechanism Of Action

PL-8177 - Drug Profile

Product Description

Mechanism Of Action

PL-8331 - Drug Profile

Product Description

Mechanism Of Action

PL-9643 - Drug Profile

Product Description

Mechanism Of Action

PL-9654 - Drug Profile

Product Description

Mechanism Of Action

PMC-401 - Drug Profile

Product Description

Mechanism Of Action

PMC-403 - Drug Profile

Product Description

Mechanism Of Action

Protein for Metabolic Disorders, Oncology and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

PT-698 - Drug Profile

Product Description

Mechanism Of Action

PTG-6 - Drug Profile

Product Description

Mechanism Of Action

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

ranibizumab SR - Drug Profile

Product Description

Mechanism Of Action

RBM-008 - Drug Profile

Product Description

Mechanism Of Action

RC-28 - Drug Profile

Product Description

Mechanism Of Action

REG-001 - Drug Profile

Product Description

Mechanism Of Action

Resolvine ER - Drug Profile

Product Description

Mechanism Of Action

Retinopathies - Drug Profile

Product Description

Mechanism Of Action

RG-7774 - Drug Profile

Product Description

Mechanism Of Action

RGX-314 - Drug Profile

Product Description

Mechanism Of Action

RO-5461111 - Drug Profile

Product Description

Mechanism Of Action

RPEC-1009a - Drug Profile

Product Description

Mechanism Of Action

RT-002 - Drug Profile

Product Description

Mechanism Of Action

runcaciguat - Drug Profile

Product Description

Mechanism Of Action

SB-2 - Drug Profile

Product Description

Mechanism Of Action

SBT-200 - Drug Profile

Product Description

Mechanism Of Action

SER-130 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Chronic Kidney Disease and Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Block Cav1.3 and Free Radicals for Central Nervous System, Metabolic Disorders and Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit TRAP1 for Diabetic Retinopathy and Wet Age Related Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Agonize Sigma-1 Receptor for Metabolic and Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize Renin-Prorenin Receptor for End-Organ Damage - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit ARF6 for Macular Degeneration and Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit PDGFR and VEGFR for Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit VAP-1 for Ophthalmology and Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

sorafenib tosylate - Drug Profile

Product Description

Mechanism Of Action

Spx-815 - Drug Profile

Product Description

Mechanism Of Action

ST-266 - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Diabetic Retinopathy, Peripheral Arterial Disease and Unspecified Cardiovascular Disorders, and Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

SYL-136001v10 - Drug Profile

Product Description

Mechanism Of Action

SYL-1801 - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide for Age-Related Macular Degeneration and Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

SZN-413 - Drug Profile

Product Description

Mechanism Of Action

tarcoicimab tedromer - Drug Profile

Product Description

Mechanism Of Action

TATX-21 - Drug Profile

Product Description

Mechanism Of Action

TGT-101 - Drug Profile

Product Description

Mechanism Of Action

THR-687 - Drug Profile

Product Description
Mechanism Of Action
Tie2/VEGF bi-specific - Drug Profile
Product Description
Mechanism Of Action
TMI-018 - Drug Profile
Product Description
Mechanism Of Action
tonabersat - Drug Profile
Product Description
Mechanism Of Action
TOPV-122 - Drug Profile
Product Description
Mechanism Of Action
TRV-32R - Drug Profile
Product Description
Mechanism Of Action
UBX-1325 - Drug Profile
Product Description
Mechanism Of Action
UBX-1967 - Drug Profile
Product Description
Mechanism Of Action
UBX-2050 - Drug Profile
Product Description
Mechanism Of Action
VLTR-557 - Drug Profile
Product Description
Mechanism Of Action
vorolanib - Drug Profile
Product Description
Mechanism Of Action
VT-1001 - Drug Profile
Product Description
Mechanism Of Action
Wnt-001 - Drug Profile
Product Description
Mechanism Of Action
XW-006 - Drug Profile

Product Description

Mechanism Of Action

YDB-201 - Drug Profile

Product Description

Mechanism Of Action

ziv-aflibercept - Drug Profile

Product Description

Mechanism Of Action

Diabetic Retinopathy - Dormant Projects

Diabetic Retinopathy - Discontinued Products

Diabetic Retinopathy - Product Development Milestones

Featured News & Press Releases

Oct 19, 2022: OcuTerra reports publication of OTT166 safety and biological activity data from phase 1b study in diabetic eye disease

Oct 14, 2022: OcuPhire Pharma hosting Key Opinion Leader event on oral APX3330 for diabetic eye disease

Sep 29, 2022: EyePoint Pharmaceuticals announces first patient dosed in phase 2 PAVIA clinical trial of EYP-1901 for the treatment of non-proliferative diabetic retinopathy

Sep 26, 2022: Surrozen publishes study in Translational Vision Science and Technology demonstrating the promise of SZN-413 in preclinical models of diabetic retinopathy

Sep 19, 2022: Coherus to launch CIMERLI (ranibizumab-eqrn) in the United States on October 3, 2022

Sep 08, 2022: OcuPhire Pharma announces last patient completes final visit in ZETA-1 phase 2b 24-week trial of oral APX3330 in diabetic retinopathy

Aug 18, 2022: Valo Health announces first patient dosed in the OPL-0401 phase 2 study of an oral ROCK1/2 inhibitor for the treatment of non-proliferative diabetic retinopathy

Aug 05, 2022: Kodiak Sciences completes enrollment in GLOW phase 3 clinical trial of Tarcocimab Tedromer (KSI-301) in patients with non-proliferative diabetic retinopathy

Aug 02, 2022: FDA approves Coherus' CIMERLI (ranibizumab-eqrn) as the first and only interchangeable biosimilar to Lucentis for all five indications, with 12 months of interchangeability exclusivity

Aug 02, 2022: OcuTerra Therapeutics announces first patient dosed in OTT166 phase 2 DR:EAM clinical trial for diabetic retinopathy

Jun 29, 2022: OcuPhire granted new U.S. patent for late-stage oral drug candidate APX3330 for use in diabetics and announces new peer-reviewed APX3330 publication

Jun 29, 2022: EYLEA (aflibercept) injection sBLA for Every 16-week dosing regimen in

patients with diabetic retinopathy accepted for FDA review

Jun 11, 2022: Ocuphire to present new interim masked safety data for oral APX3330 in Diabetics at Annual Macula Society Meeting

May 11, 2022: Ocuphire Pharma announces upcoming presentations at the Retina World Congress, clinical trials at the Summit, and the H.C. Wainwright Global Investment Conference

May 02, 2022: Palatin to present on PL-9654 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Diabetic Retinopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Diabetic Retinopathy - Dormant Projects, 2022
Diabetic Retinopathy - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Diabetic Retinopathy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/DAEDE20136C3EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DAEDE20136C3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

